title: Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients.
abstract: Survival of solid organ transplant patients has been prolonged, leading to increased incidence of non-melanoma skin cancers. Metastatic squamous cell carcinoma is an increasing problem in these patients. This paper reviews the evidence available for the treatment of advanced squamous cell carcinoma with the epidermal growth factor receptor inhibitor, cetuximab.
authors.affiliation: Department of Pathology, University of Virginia, Charlottesville, USA. klcraven@gmail.com
authors.forename: Katherine
authors.initials: K
authors.lastname: Boyd
authors.forename: Sofia M
authors.initials: SM
authors.lastname: Shea
authors.forename: James
authors.initials: J
authors.lastname: Patterson
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D000068818:Cetuximab; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000068818:Cetuximab